Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab added to gemcitabine-based chemoradiation for unresectable non-metastatic pancreatic cancer
NL-OMON25995Phase 2Recruiting
- Sponsor
- Prof. dr. H.M.W. Verheul, M.D., Ph.D. Head Department of Medical Oncology VU University Medical Center De Boelelaan 1117 1081 HV Amsterdam Phone: +31-20-4444321/300 Fax: + 31-20-4444079 Email: [email protected]
- Start
- Jul 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab and gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by Prof. dr. H.M.W. Verheul, M.D., Ph.D. Head Department of Medical Oncology VU University Medical Center De Boelelaan 1117 1081 HV Amsterdam Phone: +31-20-4444321/300 Fax: + 31-20-4444079 Email: [email protected]. Primary endpoints: Recommended safe dose / maximum tolerated dose, Progression-free at 7 months and 1 more. Started Jul 2010; status: recruiting.
02
Drugs
panitumumabgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON25995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25995.